Cibus, Inc. Announces Intended Public Offering of Class A Common Stock Page 1

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock in an underwritten public offering. Cibus also expects to grant the underwriters of the offering a 45-day option to purchase up to 15% of the shares of Class A common stock offered in the underwritten public offering on the same terms. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Certain existing institutional and accredited investors and Rory Riggs, Chief Executive Officer of Cibus, have expressed interest in purchasing shares of Class A common stock in this offering. Because these indications of interest are not binding agreements or commitments to purchase, those certain existing investors and Mr. Riggs may elect not to purchase shares in this offering, or the underwriters may elect not to sell shares in this offering to those certain existing investors or Mr. Riggs.

Roth Capital Partners and AGP/Alliance Global Partners are acting as joint bookrunning managers for the offering.